Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Diagnostics restructuring

This article was originally published in The Gray Sheet

Executive Summary

Business unit will lay off about 1,100 employees worldwide and reorganize into four operations focusing on immunochemistry, hematology, molecular and blood glucose monitoring. Worldwide diagnostics sales of $733 mil. in the third quarter were basically flat (up 0.8%), including a 9% decline in U.S. diagnostics revenues to $288 mil. Abbott notes it has hired Bio-Reg and AccuReg as new third-party consultants to assist in resolving its 1999 FDA consent decree. The diagnostics restructuring is part of a larger plan to increase bottom-line accountability and save $80-100 mil. annually by 2005, Abbott notes. Company-wide, 2,000 positions will be cut, or 3% of Abbott's workforce, and ten facilities shuttered. A fourth-quarter charge of $100-125 mil. will be recorded...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT017284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel